Key facts
- Nested Therapeutics’s last known valuation is $203.2M.
- It has raised $128.2M; the latest was Early Stage VC ($3.2M) in Aug 2024.
- Notable investors include Blue Owl Capital, S32, Foresite Capital, Avidity Partners, Versant Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Nested Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Nested Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nested Therapeutics
Operator of a medical research firm intended to develop precision oncology medicine therapies by finding new driver mutations. The company discovers novel, targeted, small-molecule precision oncology medicine by using mutation clusters to identify druggable pockets with a platform that utilizes insights from genomics, computational chemistry, proteomics, and AI, enabling healthcare professionals to better treat patients with precision medication.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 19
- Website
- nestedtx.com/
- Ownership
- Privately Held (backing)
Nested Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nested Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nested Therapeutics in its N-PORT filings yet. We sweep new filings monthly.